Discover why biomarkers are critical in modern drug discovery and clinical trials, enabling better target validation.
On Wednesday, the U.S. Food and Drug Administration (FDA) published three new draft guidances that aim to offer greater clarity to sponsors of cell and gene therapies (CGTs) on issues related to ...
StockStory.org on MSN
A look back at drug development inputs & services stocks’ Q4 earnings: Charles River Laboratories (NYSE:CRL) vs the rest of the pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...
Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 ...
Clinical Trials suffer due to inherent inefficiencies in manual workflows built on fragmented systems. It's time for a ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
Soo-Kyung and Jae Lee, whose daughter has FOXG1 syndrome, developed the gene therapy that could one day treat people with this severe disorder.
The Food and Drug Administration (FDA) has issued a new guidance document entitled “Enhancing Participation in Clinical Trials – Eligibility Criteria, Enrollment Practices, and Trial Decision.” The ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...
Sponsor-initiated trial closure can abruptly end access despite exceptional individual benefit, underscoring the need for contingency planning for drug supply, follow-on protocols, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results